Search results
Hugh Auchincloss, Jr. (pronounced: aa-kuhn-klaas; born March 15, 1949) is an American immunologist and physician serving as the acting director of the National Institute of Allergy and Infectious Diseases since 2023.
Sep 24, 2023 · Hugh Auchincloss, M.D., serves as NIAID Principal Deputy Director. In this capacity, Dr. Auchincloss is responsible for the following: Providing leadership for all NIAID research planning and implementation activities, including helping to prepare and support a strategic vision for NIAID
Nov 28, 2022 · This is an oral history with Dr. Hugh Auchincloss, Jr., on November 28, 2022, about his career at the National Institute of Allergy and Infectious Diseases (NIAID).
About Hugh Auchincloss, MD. Dr. Auchincloss received his M.D. from Harvard Medical School in 2008. He completed his General Surgery and Cardiothoracic Surgery training at the Massachusetts General Hospital and joined the Division of Thoracic Surgery in 2018.
The Auchincloss Laboratory, led by Hugh Auchincloss, MD, MPH, in the Division of Thoracic Surgery at Massachusetts General Hospital, uses institutional data combined with large national and international databases to answer questions about the treatment and prognosis of lung cancer and other thoracic surgery diseases.
Auchincloss is associate professor of surgery at Harvard Medical School and associate visiting surgeon at Massachusetts General Hospital, as well as chair of the FDA's Subcommittee on Xeno ...
Jan 20, 2023 · Dr. Hugh Auchincloss has agreed to serve as acting director of the National Institute of Allergy and Infectious Diseases (NIAID). Auchincloss assumed the acting role on Jan. 1. He has served as NIAID’s principal deputy director since joining NIH in 2006.
Oct 17, 2023 · Dr. Hugh Auchincloss, NIAID Principal Deputy Director, welcomes the NIAID DP2 New Innovator awardees and is proud to support these exceptional early-career investigators in their movement into independent positions.
- www.nih.gov
- › News & Events
- › News Releases
Sep 22, 2023 · “The evidence is clear that immune modulation can be beneficial for severely ill COVID-19 patients,” said NIAID Acting Director Hugh Auchincloss, M.D. “Patients with milder cases of COVID-19 are often administered one immune modulator, and a second treatment is added only if the patient becomes severely ill.
Feb 10, 2023 · Auchincloss, 73, a respected transplant surgeon and medical researcher, served for more than 16 years as Fauci’s low-key right-hand man at NIAID, a post he took after a long career at...
